Local linear spatial regression

A local linear kernel estimator of the regression function x\mapsto g(x):=E[Y_i|X_i=x], x\in R^d, of a stationary (d+1)-dimensional spatial process {(Y_i,X_i),i\in Z^N} observed over a rectangular domain of the form I_n:={i=(i_1,...,i_N)\in Z^N| 1\leq i_k\leq n_k,k=1,...,N}, n=(n_1,...,n_N)\in Z^N, is proposed and investigated. Under mild regularity assumptions, asymptotic normality of the estimators of g(x) and its derivatives is established. Appropriate choices of the bandwidths are proposed. The spatial process is assumed to satisfy some very general mixing conditions, generalizing classical time-series strong mixing concepts. The size of the rectangular domain I_n is allowed to tend to infinity at different rates depending on the direction in Z^N.Comment: Published at http://dx.doi.org/10.1214/009053604000000850 in the Annals of Statistics (http://www.imstat.org/aos/) by the Institute of Mathematical Statistics (http://www.imstat.org

Tie Turning Box-Cox including Quadratic Forms in Regression

In a regression model where a Box-Cox transformation is used on a positive independent variable X which appears only once in the equation, the effect of X on the dependent variable Y is either strictly increasing or decreasing over the whole range of X , since the transformation is a monotonic function of X , increasing or decreasing depending on the Box-Cox parameter ë. This paper considers the case where the variable X appears twice in the regression with two different Box-Cox parameters 1 ë and 2 ë , to allow a turning point in Y which can be a maximum or minimum. First and second-order conditions for the critical point are derived. This general specification includes as a special case the quadratic form in X where 1 ë and 2 ë are set equal to 1 and 2, respectively. If, instead of using the Box-Cox transformations, one uses simple powers of X , this form is equivalent to the Box-Cox form except that neither 1 ë nor 2 ë can be equal to zero, since in this case 1 ë X or 2 ë X reduces to a constant of value 1.Box-Cox Transformation, Quadratic Form, Asymmetric U-shaped Forms, Regression. Classification-JEL :

Oligonucleotides Modified With Transplatin Derivatives: Fast and Efficient Metalloribozymes

When an oligonucleotide containing a 1,3-(G,G)-transplatin cross-link at a GNG site (N represents a C, T, A or U residue) is paired with its complementary strand, the intrastrand adduct rearranges into an interstrand cross-link, resulting in the covalent attachment of both strands. Here, we have studied the influence of the inert ligands of the platinum(II) complex and of the nucleotide residues in the vicinity of the adduct on the rearrangement reaction. Dramatic effects on the linkage isomerization rate could be 37℃. The results are analyzed in relation with the mechanism of rearrangement of the 1,3-intrastrand adducts into interstrand cross-links. The relevance of platinated oligonucleotides as potent and specific drugs is discussed

A functional limit theorem for lattice oscillating random walk

The paper is devoted to an invariance principle for Kemperman's model of oscillating random walk on $\mathbb{Z}$. This result appears as an extension of the invariance principal theorem for classical random walks on $\mathbb{Z}$ or reflected random walks on $\mathbb{N}_0$. Relying on some natural Markov sub-process which takes into account the oscillation of the random walks between $\mathbb{Z}^-$ and $\mathbb{Z}^+$, we first construct an aperiodic sequence of renewal operators acting on a suitable Banach space and then apply a powerful theorem proved by S. Gou\"ezel

Gait analysis with curvature maps: A simulation study

Gait analysis is an important aspect of clinical investigation for detecting neurological and musculoskeletal disorders and assessing the global health of a patient. In this paper we propose to focus our attention on extracting relevant curvature information from the body surface provided by a depth camera. We assumed that the 3D mesh was made available in a previous step and demonstrated how curvature maps could be useful to assess asymmetric anomalies with two simple simulated abnormal gaits compared with a normal one. This research set the grounds for the future development of a curvature-based gait analysis system for healthcare professionals.Comment: 4 pages, 5 figure

The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: A literature-based economic analysis

Jennifer Stephens, Kimbach Tran Carpiuc, Marc BottemanPharmerit North America LLC, Bethesda, MD, USAObjectives: To develop an economic analysis of the management of pleural effusions in patients with imatinib-resistant/intolerant chronic myelogenous leukemia (CML).Methods: A cost of treatment analysis was conducted from the US payer perspective, based on resource utilization data for 48 patients with dasatinib-related pleural effusions at a large US cancer center. Probabilities of various procedures and treatment events were derived from published resource use data, supplemented with expert opinion. Cost data was derived from median reimbursements for relevant CPT codes for outpatient services and medical literature for inpatient services. Sensitivity analyses were conducted for types of procedures used. All costs were adjusted to US dollars (2007 rates).Results: Sixty percent of pleural effusions were managed medically costing 750 per episode. Forty percent of pleural effusions were more significant (>25% of one lung volume), with half of those requiring invasive procedures. Cost of inpatient procedures was 10,616 for chest tube and $15,170 with pleural catheter. Cost of outpatient procedures was$713 for ultrasound thoracentesis and $4,598 for pleural catheter. The average cost of treating a pleural effusion was$2,062 to >$2,700 for all severity levels and ~$6,400 to >$9,000 for invasive procedures. Key cost drivers were invasive procedures and recurrence.Conclusion: This economic analysis using actually observed treatment patterns suggests that the management of pleural effusion adverse events in CML patients is costly, requires intensive resource utilization, and may be an important factor in treatment selection.Keywords: dasatinib, nilotinib, imatinib, adverse events, safety, cost, and cost analysi